Hmpv in Northern California Reveals a Paradox: Rising Wastewater Signals but No Vaccine or Treatment
hmpv is showing up in sewer surveillance and clinical testing across parts of California even as there is no licensed vaccine or targeted antiviral therapy — a gap underscored by a national test-positivity peak of 11. 7% in a recent season. The pattern raises questions about preparedness, public messaging and who is most at risk.
Hmpv wastewater signals: what the monitoring data show
Data from the WastewaterScan Dashboard indicate high concentrations of human metapneumovirus in a majority of Northern California communities sampled. Local increases in wastewater levels were observed in Merced in the San Joaquin Valley and in Novato and Sunnyvale in the San Francisco Bay Area between mid-December and the end of February. L. A. County has detectable HMPV in sewage at levels described as low to moderate in available monitoring.
Verified facts: the WastewaterScan Dashboard is the named public database used to track these detections; the named communities cited above appear in the monitoring data as having increases over the specified period.
What clinicians and surveillance systems say about transmission, seasonality and testing trends
Dr. Neha Nanda, chief of infectious diseases and hospital epidemiologist for Keck Medicine of USC, states that human metapneumovirus is transmitted by close contact with infected people and by touching contaminated surfaces. Dr. Jessica August, chief of infectious diseases at Kaiser Permanente Santa Rosa, outlines a typical seasonal pattern in which HMPV cases commonly begin in January, peak in March or April and tail off in June, while noting that the COVID-19 pandemic disrupted those seasonal norms.
National testing data from the National Respiratory and Enteric Virus Surveillance System document recent seasonal peaks: a national peak test positivity of 11. 7% at the end of one season, a 7. 15% peak the following year, and a most-recent documented high of 6. 1% on February 21 for the current reporting period. The U. S. Centers for Disease Control and Prevention records that HMPV was first detected in 2001.
Analysis: Clinician statements and surveillance numbers together show a virus that follows recognizable seasonal timing but whose prevalence and impact have been altered by recent population-level shifts in immunity and behavior. The wastewater detections in specific California communities create an early-warning signal that mirrors the upward movement seen in clinical test positivity nationally.
What is not being told — and what officials should explain
Verified facts: there is no licensed vaccine for human metapneumovirus and no specific antiviral treatment regimen named in the available material. Dr. August notes that routine exposure before the pandemic contributed to baseline immunity in the population and that reduced exposure during the COVID-19 era led to diminished population immunity and larger outbreaks among children when contacts resumed; she also says many of those disruptions have since moderated.
Analysis: The combination of rising wastewater signals in parts of California, national test-positivity figures that have reached into double digits in prior seasons, and the absence of a vaccine or targeted therapy presents a communication and policy gap. Public health decision-makers would better serve communities by explaining how sewage surveillance maps onto clinical risk, what groups should be especially vigilant, and how testing and hospital-capacity indicators will be used to guide interventions.
Accountability conclusion: With wastewater and clinical surveillance both showing activity, named surveillance systems and clinical leaders — including the National Respiratory and Enteric Virus Surveillance System, the U. S. Centers for Disease Control and Prevention, Dr. Neha Nanda of Keck Medicine of USC and Dr. Jessica August of Kaiser Permanente Santa Rosa — provide the factual basis for public guidance. Clearer public communication, routine publication of local wastewater and testing thresholds tied to actionable guidance, and stronger outreach to clinicians and high-risk populations are warranted so that communities understand what rising hmpv signals actually mean for everyday risk and care-seeking.
